Alphabet's Isomorphic Labs raised $5 billion in Series C funding for AI drug design

Quartz

Source published: Site published:

Original article

Isomorphic Labs, a company owned by Alphabet ($GOOGL), has raised $5 billion in a Series C funding round, the company said on Tuesday. It will use the money to expand its AI system for designing drugs and move its first possible medicines closer to testing in people.

Greenoaks and Sequoia Capital led the funding round together. Andreessen Horowitz and several other new investors also took part. Alphabet continued to provide major financial support. The company said in a news release that all its existing investors also joined the round: Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K. Sovereign AI Fund.

“This round allows us to move faster: building basic AI models of biology, improving our understanding of diseases and moving our first drug programs toward clinical trials so they can make a real difference for patients,” said Sir Demis Hassabis, founder and CEO of Isomorphic Labs, in a statement reported by CNBC.

The company said it will use the money to expand IsoDDE, its drug design system. The system uses AI models to simulate how drugs work across different types of diseases and treatments. The money will also help build the systems and teams needed to develop drugs and prepare them for clinical trials. The company said its own cancer and immune system research programs, as well as projects with partners, have shown positive results in tests before human trials.

“We're trying to build a platform that can develop hundreds of drugs each year,” Hassabis told Bloomberg. Bloomberg reported that Isomorphic has more than 20 programs in progress.

In January, Hassabis said the company hoped to start testing its first drugs in clinical studies before the end of 2026, according to Bloomberg. When asked about this in November, he did not give a new date. He said the paperwork needed for regulatory approval of the first cancer program was moving forward as planned. He also said the company would share more news in 2027.

Isomorphic did not say how much the company is worth, according to Bloomberg. An earlier Bloomberg report said the company was preparing to raise $5 billion at a value of about $50 billion.

In August, Alphabet announced changes to its leadership. Hassabis would leave his job as CEO of Google DeepMind and become the group's chairman and Alphabet's chief scientist. He would continue to lead Isomorphic.

The new funding round comes after Isomorphic raised $2.1 billion in a Series B round in May, according to CNBC. Companies working to discover new drugs have raised a record $23.2 billion in 2026.